Table 1.
Summary of HLA-A mismatches between lung allograft donors and recipients, and clinical features following human lung transplantation.
I.D. | Diseasea | LTxb | HLA-A allele: Donor | HLA-A allele:Recipient | DSA-Ac | Auto Abd | BOSe | ARf | ||
---|---|---|---|---|---|---|---|---|---|---|
P1 | CF | 1 | A2 | A33 | A3 | A68 | + | +++ | 2 | 2 |
P2 | IPF | 1 | A3 | A33 | A2 | A24 | + | ++ | 3 | 2 |
P3 | IPF & RA | 1 | A3 | A3 | A2 | A24 | +/− | + | 0-p | 1 |
P4 | COPD | 1 | A2 | A26 | A3 | A11 | +/− | +/− | Neg | 2 |
P5 | A1AD | 1 | A2 | A2 | A25 | A32 | + | ++ | 1 | 1 |
P6 | IPF | 1 | A2 | A3 | A24 | A25 | +/− | ++ | 1 | 2 |
P7 | IPF | 1 | A2 | A30 | A66 | A69 | +/− | + | Neg | 1 |
P8 | COPD | 1 | A3 | A68 | A43 | A68 | +/− | ++ | Neg | 2 |
P9 | CF | 1 | A2 | A29 | A11 | A30 | + | +/− | 0-p | 1 |
P10 | CTD | 1 | A2 | A34 | A69 | A80 | + | +++ | 2 | 2 |
P11 | CF | 1 | A11 | A33 | A3 | A24 | + | ++ | Neg | 2 |
P12 | COPD | 1 | A11 | A33 | A2 | A3 | + | ++ | 0 | 1 |
P13 | IPF | 1 | A30 | A32 | A3 | A68 | + | +++ | 1 | 3 |
P14 | CF | 1 | A24 | A66 | A2 | A31 | +/− | + | 0-p | 2 |
P15 | PAH | 1 | A69 | A80 | A3 | A26 | + | +/− | Neg | 2 |
CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; RA, rheumatoid arthritis; COPD, chronic obstructive pulmonary disease; A1AD, alpha 1 anti-trypsin deficiency; CTD, connective tissue disease; PAH, pulmonary arterial hypertension
1, primary transplantation (bilateral); 2, re-transplantation (bilateral)
DSA determination performed by LABScreen Single Antigen assay (One Lambda Inc): +, persistent/ recurrent DSA; +/−, resolved DSA; −, DSA negative
Ab to Collagen V or Kα1Tubulin measured by ELISA: +++, strong positive; ++, moderate positive; +, weak positive; −, negative
Bronchiolitis Obliterans Syndrome (BOS) grade at clinical diagnosis; Neg, negative for BOS
Grade of acute rejection (AR)